Slides
Page 1
MARKER THERAPEUTICS CORPORATE PRESENTATION June 2025 NASDAQ: MRKR
Page 2
Forward Looking Statements Certain statements contained herein are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, that involve risks and uncertainties. All statements other than statements relating to historical matters including statements to the effect that we “believe”, “expect”, “anticipate”, “plan”, “target”, “intend” and similar expressions, including without limitation statements regarding Marker Therapeutics, Inc.’s (“Marker” or the “Company”) intentions, beliefs, projections, outlook, analyses or current expectations are “forward-looking statements”. Forward-looking statements include statements concerning, among other things: the Company’s research, development and regulatory activities and expectations relating to its non-engineered multi-tumor associated antigen (multiTAA)-specific T cell therapies; the effectiveness of the Company’s programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the timing, conduct and success of the Company’s clinical trials of its product candidates, including MT-401 for the treatment of patients with Acute Myeloid Leukemia (“AML”) or Myelodysplastic Syndrome (“MDS”), MT-401 Off- the-Shelf (“OTS”) for the treatment of patients with AML, and MT-601 for the treatment of patients with relapsed lymphoma; the Company’s long- term stability and cash runway; the Company’s optimized manufacturing process; and the future development of multiTAA-specific T cells. Forward- looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Forms 10-K, 10-Q and other SEC filings which are available through EDGAR at WWW.SEC.GOV. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, the fairness, accuracy or completeness of the information contained herein. Accordingly, none of the Company, or any of its principals, partners, subsidiaries or affiliates, or any of such person’s board members, officers or employees accepts any liability whatsoever arising directly or indirectly from the use of this presentation. Certain information set forth herein includes estimates, projections and targets and involves significant elements of subjective judgement and analysis, which may or may not be correct. No representations are made as to the accuracy of such estimates, projections or targets or that all assumptions relating to such estimates, projections or targets have been considered or stated or that such estimates, projections or targets will be realized. This presentation does not purport to contain all of the information that may be required to evaluate the Company and any recipient hereof should conduct its own independent analysis of the Company and the data and information contained herein. Any forward-looking statements are not guarantees of future performance and actual results may differ materially from estimates in the forward-looking statements. Unless otherwise stated, all information in this presentation is as of the date of the cover page of this presentation, and the Company undertakes no obligation to revise these forward-looking statements to reflect events or circumstances that arise after the date hereof. 2
Page 3
3 MAR-T Cell Platform Attractive Safety Profile MT-601 – Lead Clinical Product MAR-T (Multi-Antigen Recognizing T cell, formerly known as multiTAA) technology was developed at Baylor College of Medicine and, we believe, offers key therapeutic and manufacturing advantages over traditional T cell therapies MAR-T cells are non-genetically engineered and were well-tolerated in clinical trials to date, with a favorable safety profile and no observation of immune-effector cell associated neurotoxicity syndrome (ICANS) attributed to MAR-T cell technology Marker’s lead product, MT-601, targets 6 tumor-specific antigens (Survivin, PRAME, NY-ESO-1, MAGE-A4, SSX2, WT-1) for a broad tumor recognition MT-601 - APOLLO Study MT-601 in Phase 1 clinical trial has shown 78% response rates in patients with lymphoma who relapsed after anti-CD19 CAR-T cells or where CAR-T cell therapy is not an option Multiple INDs & Strong IP Position FDA cleared INDs for three MAR-T based clinical programs Strong IP position and world-wide exclusive license on MAR-T technology from Baylor College of Medicine Non-Dilutive Funding Support Ongoing efforts to obtain non-dilutive funding; to date Marker was awarded over $30 million non-dilutive funding (NIH, FDA, CPRIT) Marker Therapeutics – Value Proposition
Page 4
MAR-T Technology 4
Page 5
Multi Antigen Recognition Multi Epitope Recognition Low Risk for CRS or ICANS For Blood & Solid Tumors Intra- & Extra- Cellular Targets No Genetic Engineering 5 • MAR-T cells recognize up to 6 antigens1, 2 for a more potent, durable anti-tumor response. • MAR-T cells lack genetic modification; Natural T cells expanded ex vivo pose no mutagenesis risk. • MAR-Ts intend to address challenges faced by Bispecific Antibodies, CAR-T and TCR approaches. • MAR-T platform technology developed at Baylor College of Medicine. Mechanism of Action of MAR-T Cells (1) MT-601 targets six tumor antigens (Survivin, PRAME, NY-ESO-1, WT-1, MAGE-A4, SSX2). (2) MT-401 targets four tumor antigens (Survivin, PRAME, NY-ESO-1, WT-1). Overlapping peptides PBMC isolation MAR-T cells Activation Expansion & Infusion TCR FASL Apoptosis PRAME Survivin NY - ESO - 1 WT - 1 SSX2 MAGE - A4 Tumor cell TRAIL MAR-T cells
Page 6
• Lack of genetic engineering • Natural T cell expansion • Uninterrupted cell expansion • Reproducible process • Cost-effective process PBMC, peripheral blood mononuclear cells. 6 MAR-T Cells are Generated in a Simple Manufacturing Process
Page 7
MAR-T Pipeline for Hematologic Malignancies and Solid Tumors 7 PROGRAM / INDICATION PRECLINICAL IND PHASE 1 PHASE 2 HEMATOLOGIC MALIGNANCIES MT-601 (APOLLO) Lymphoma – Patient Specific MT-401-OTS AML – Off-the-Shelf (OTS) SOLID TUMORS MT-601 Pancreatic Cancer – Patient Specific AML, Acute Myeloid Leukemia.
Page 8
MT-601 MAR-Ts targeting 6 tumor antigens for patients with lymphoma who relapsed after anti-CD19 CAR-T cells or where CAR-T cell therapy is not an option 8
Page 9
9 HL: Hodgkin’s Lymphoma; NHL: Non-Hodgkin’s Lymphoma Pre-Infusion Month 9 • Study conducted at Baylor College of Medicine • MAR-Ts targeting 5 tumor-specific antigens • Excellent Safety Profile • Lack of CRS and ICANS • Durable Complete Responses for up to 5 years Durability of Response MAR-Ts (targeting 5 tumor antigens) showed durable Complete Responses Potent and Specific MAR-Ts have shown potent and specific anti-tumor activity Previous Phase 1 Study using MAR-Ts Showed Durable Responses in Patients with Lymphoma Vasileiou S et al. J Clin Oncol 2021. TACTAL study, ClinicalTrials.gov Identifier: NCT01333046.
Page 10
MT-601 is an Optimized MAR-T Cell Product 10 MARKER’S MT-601 STUDYBAYLOR STUDY • Study at Baylor College of Medicine targeted 5 tumor antigens with durable responses for up to 5 years without CRS or ICANS (1) • Cell Dose: 50x106 – 100x106 • Manufacturing Process: • Average Potency: 77 SFU/ 2x105 cells • Broader Target Specificity: Marker’s process targets 6 tumor antigens • Higher Cell Dose: 200x106 – 400x106 • Improved Manufacturing Process: • 4x increased potency (Average Potency: 1,200 SFU/ 2x10 5 cells) (1) Vasileiou S et al. J Clin Oncol 2021. TACTAL study, ClinicalTrials.gov Identifier: NCT01333046.
Page 11
CD19-negative lymphoma cell outgrowth 0 5 10 15 20 25 0 20 40 60 Days in vitro Lymphoma Cell Growth Fold Change in Lymphoma Cell Growth Control Lymphoma anti-CD19 CAR-T infused Lymphoma 0 5 10 0 20 40 60 80 100 Fold Change in Lymphoma Cell Growth Control Lymphoma anti-CD19 CAR-T infused Lymphoma CD19 Antigen FSC 98% 0.34% CD19 Antigen FSC 0 5 10 15 20 25 0 20 40 60 80 100 Daysin vitro Lymphoma Cell Growth Fold Change in Lymphoma Cell Growth Control Lymphoma MT-601 infused Lymphoma CD19 antigen-negative lymphoma cell outgrowth is CAR refractory CAR refractory lymphoma is controlled by MT-601 MT-601 Demonstrates Anti-Tumor Activity in CAR Relapsed Lymphoma Cells In Vitro MT-601 kills CD19 CAR-T refractory lymphoma cells 11
Page 12
MT-601 Shows Early Objective Responses 12 APOLLO Study Highlights Pre-Infusion After MT-601 Infusion Study participant diagnosed with DLBCL had 10 prior treatment lines (incl. bispecific antibodies and anti-CD19 CAR-Ts). Study participant achieved Complete Response at first response assessment.(1) DLBCL, Diffuse Large B Cell Lymphoma. (1) Presentation by Geoffrey Shouse, 11th Global Summit on Hematologic Malignancies, Whistler 2024. Response 0 20 40 60 80 100Percentage (%) Complete Response Partial Response Progressive Disease at first assessment Response Rates 78% Objective Response Rates Objective Responses in Patients Who Have Been Heavily Pre-Treated • Safety No observation of ICANS. • Efficacy In first dose cohort, 7 out of 9 patients achieved objective responses (78%) at first response assessment.
Page 13
13 Study Participants show Early Objective Responses Complete Response Partial Response CR, Complete Response; PR, Partial Response; PD, Progressive Disease; LoT, Line of Therapy; FL, Follicular Lymphoma; LBCL, Large B Cell Lymphoma; MZL , Marginal Zone Lymphoma; MCL, Mantle Cell Lymphoma. Patient ID Disease Histology No. prior LoT CAR-T Therapy Bispecific Antibodies Response at First Assessment 1 LBCL 4 Yes No CR 2 LBCL/FL 12 Yes Yes CR 3 FL/LBCL 3 No No PR 4 LBCL 5 Yes No PD 5 LBCL 5 Yes No PD 6 LBCL 3 No No PR 8 MCL 5 Yes No PR 7 LBCL 10 Yes Yes CR 9 MZL 6 No No CR
Page 14
Future Developments 14
Page 15
MT-601 in Pancreatic Cancer MT-401-OTS & MT-601 – Advancing Allogeneic and Solid Tumor Programs 15 MT-401 Off-the-Shelf • Manufactured from healthy donors; Marker has cellular inventory with plans to expand • PoC studies completed with data supporting clinical benefits of technology • IND to investigate MT-401 in an “Off-the-Shelf” setting (MT-401-OTS) in AML or Myelodysplastic Syndrome (MDS) granted by FDA • Orphan Drug Designation granted by FDA and the European Medicines Agency (EMA) • Non-dilutive funding from FDA, CPRIT and NIH to support clinical investigation of MT-401-OTS in patients with AML • FDA has granted an IND to investigate MT-601 in patients with metastatic pancreatic cancer in combination with front-line chemotherapy • Marker received $9.5 million from CPRIT and $2 million from NIH SBIR to support the investigation of MT-601 in patients with pancreatic cancer PoC, Proof-of-Concept.
Page 16
Key Takeaways 16 In contrast to single antigen-targeting T cell therapies, MAR-Ts target multiple epitopes within up to 6 tumor-specific antigens, thereby reducing the possibility of tumor escape MAR-Ts do not require genetic engineering APOLLO study highlights: • MT-601 was well-tolerated with no signs of ICANS. • First dose cohort: 7 out of 9 patients (78%) achieved objective responses at first response assessment, with 4 complete responses.
Page 17
THANK YOU 17